GlassScriptPhysician profile
Marissa Davidson
NPI 1760223218
$4,327.30
in general payments reported to CMS, 2019-2025
46 companies · $2,766 in 2025
The $2,766 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,561 · 2025: $2,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,153 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,153.31 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $401.33 | 2024-2025 | |
| Daiichi Sankyo INC. | $352.36 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Astrazeneca Pharmaceuticals LP | $283.89 | 2024-2025 | Calquence, Enhertu, Lynparza |
| Glaxosmithkline, LLC. | $255.55 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Janssen Biotech, INC. | $243.53 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $233.42 | 2024-2025 | Vpriv, Alunbrig, Ninlaro |
| Incyte Corporation | $210.60 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Pharmaessentia USA Corporation | $155.57 | 2024-2025 | Besremi |
| Pfizer INC. | $153.54 | 2024-2025 | |
| Abbvie INC. | $132.00 | 2024-2025 | |
| Genentech USA, INC. | $130.22 | 2024-2025 | Itovebi, Polivy, Tecentriq |
| Merck Sharp & Dohme LLC | $130.04 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Exelixis INC. | $120.98 | 2024-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $120.14 | 2024-2025 | Libtayo |
| Beigene USA, INC. | $110.00 | 2024 | Brukinsa |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $109.06 | 2024-2025 | Opdivo |
| Eisai INC. | $104.91 | 2024-2025 | |
| Novocure INC. | $104.66 | 2024 | Optune Lua (Novottf-200t) |
| Bayer Healthcare Pharmaceuticals INC. | $79.67 | 2024 | |
| Seagen INC. | $74.99 | 2025 | |
| Azurity Pharmaceuticals, INC. | $66.92 | 2024-2025 | Vivimusta, Danziten |
| Immunocore Limited | $61.83 | 2024-2025 | Kimmtrak |
| Deciphera Pharmaceuticals INC. | $51.24 | 2025 | Qinlock, Romvimza, Tgct |
| Rigel Pharmaceuticals, INC. | $48.87 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Adc Therapeutics America, INC. | $48.54 | 2025 | |
| Emd Serono, INC. | $47.63 | 2025 | |
| Iovance Biotherapeutics, INC. | $39.83 | 2025 | Amtagvi |
| Ipsen Biopharmaceuticals, INC | $39.49 | 2025 | Onivyde |
| Aveo Pharmaceuticals, INC. | $34.97 | 2025 | |
| Celgene Corporation | $32.29 | 2025 | Opdivo |
| Pharmacosmos Therapeutics INC. | $30.70 | 2025 | Monoferric |
| Alexion Pharmaceuticals, INC. | $29.76 | 2024 | |
| Tersera Therapeutics LLC | $29.15 | 2025 | Zoladex |
| Corcept Therapeutics | $26.60 | 2025 | Korlym |
| Legend Biotech USA INC. | $25.83 | 2025 | Carvykti |
| Spectrum Pharmaceuticals INC. | $24.20 | 2025 | Rolvedon |
| Sobi, INC | $23.70 | 2025 | |
| Sumitomo Pharma America, INC. | $22.13 | 2025 | Orgovyx |
| Sun Pharmaceutical Industries INC. | $21.52 | 2025 | |
| Puma Biotechnology, INC. | $20.29 | 2024 | |
| Mirati Therapeutics, INC. | $18.39 | 2024 | Krazati |
| Janssen Pharmaceuticals, INC | $16.63 | 2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $16.33 | 2024 | Givlaari |
| Molnlycke Health Care US, LLC | $16.31 | 2024 | Mepilex Border Sacrum, Mepilex Border Flex, Mlnlycke Z-Flex Fluidized Heel Boot |
| Acrotech Biopharma INC. | $13.93 | 2024 | Beleodaq |
| Caris Mpi, INC. | $13.76 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.